Improved treatment emerges for mantle cell lymphoma

Addition of ibrutinib to standard chemotherapy for patients over 65 with previously untreated mantle cell lymphoma (MCL) has led to significantly improved progression-free survival, researchers reported on June 2, 2022 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were published simultaneously in the New England Journal of Medicine. “The majority of mantle cell lymphoma patients who are […]